Peripheral Blood Flow Responses to Electromagnetic Energy
ConditionExposure to Man-made Visible Light
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-59
SponsorUniversity of Alabama at Birmingham
About this trial
This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participants will be healthy subjects over the age of 18.
Men and women will be recruited for participation.
All ethnicities will be included in this study.
Disqualifiers
age under 18 years and those over 60 years of age,
those who are unable to understand the consent process,
those who cannot read or speak English,
a history of cancer,
Trial design
Design model
Single group
Treatments tested in this trial
670 nm light
Device670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
octafluropropane
DrugOctofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: 670 nm lightExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Change in blood flow (using octafluoropropane infusion and ultrasound)
Blood flow changes based on ultrasound imaging
Time frame
10 minutesSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov